NORTH AUGUSTA, S.C.–(BUSINESS WIRE)–#CDMO—AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production while increasing our sustainability efforts. In order to meet customer needs, we continue to make state-of-the-art upgrades to our AmbioPharm South Carolina headquarters, including increasing synthesis capacity at this location.
In order to accommodate and support growth in late phase and commercial production, we have made recent installations including:
- 1M high-performance liquid chromatography column (HPLC)
- 1,000L lyophilizer
- Tangential flow filtration system with centrifuge
- Large walk in 2-8 C stability chamber
- -20 C walk in freezer
We have also added the following equipment to increase US production using greener chemistry to support manufacturing:
- CEM Liberty Blue microwave peptide synthesizer (for small scale, non-GMP solid phase peptide synthesis (SPPS))
- CEM Liberty Pro microwave peptide synthesizer (for GMP solid phase peptide synthesis (SPPS) with scales up to 15L reactor capacity)
- YMC Twin-column chromatography
The microwave peptide synthesizers enable this location to perform US crude peptide production for both nonGMP and GMP requirements, with plans for additional synthesis capacity in the future.
In addition, we have made technology investments in our Quality Organization including the implementation of Master Control as a part of the Quality Management System (QMS) as we strive to build quality into every step of our process.
These upgrades allow AmbioPharm to continue to support our customers from early phase Toxicology batches through large scale commercial manufacturing, with annual production capacity up to a metric ton. Using our expertise in peptide synthesis, we are able to tackle both simple and complex peptide projects with a proven history of success at research, clinical, and commercial scales.
About AmbioPharm, Inc.:
AmbioPharm is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with locations in the USA and Asia, AmbioPharm operates internationally with over 14 years of experience and expertise. Further information is available at: https://www.ambiopharm.com
Contacts
Mark DaFonseca, EVP, Sales & Global Business Development
mark.dafonseca@ambiopharm.com